Phase I/II tandem aCD22-aCD19 CAR-T (CART2219.1) for relapsed/refractory B-ALL: pre-infusion single-cell RNA-seq of CAR-T products
This project supports a Phase I/II trial of tandem anti-CD22/anti-CD19 CAR-T (CART2219.1) in relapsed/refractory B-cell acute lymphoblastic leukemia, with a focus on manufacturing, early clinical outcomes, and molecular response signatures. Raw sequence data include pre-infusion CAR-T cell products profiled by single-cell RNA sequencing (10x Genomics Chromium) from eight patients (four durable responders and four non-durable responders) to compare transcriptomic landscapes between response groups. Samples were processed using either immediate fresh handling or thawing followed by cell sorting to improve RNA quality for GEM formation and library preparation.